The biotechnology IPO market added another name this week as Scribe Therapeutics (NASDAQ: SCTX) priced an upsized initial public offering, raising approximately $128.7 million and…
July 24, 2026
Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical-stage biopharmaceutical company developing therapies for complement-related conditions and oncology, announced on July 23, 2026 that its partner Haisco…
Patients with metastatic clear cell renal cell carcinoma who had already progressed through multiple standard regimens went a median of 12.2 months without further progression…
NeuroSense Therapeutics is moving PrimeC one step closer to a Canadian regulatory filing, keeping its ALS story focused on a possible accelerated path to market….
July 21, 2026
Helus Hits Full Enrollment in Phase 3 APPROACH Study for Breakthrough Depression Drug HLP003
Helus Pharma (NASDAQ: HELP) has finished enrolling patients in its Phase 3 APPROACH trial of HLP003, a key step that clears the path toward late‑stage…
A reimbursement question that had hung over the stock for a year resolved in the company’s favor. Shares closed up about 35%. The policy affirms…
July 16, 2026
Dover’s CPC Biotech Launches RevolveSD™ Series, Bringing One-Inch Sterile Disconnect to Large-Scale Bioprocessing
Dover Corporation (NYSE: DOV), a diversified global manufacturer with over $8 billion in annual revenue, announced the launch of the RevolveSD™ Series on July 15,…
Galmed and partner Barcode Nanotech have built a lipid-nanoparticle version of Aramchol designed to reach cardiac tissue. The science is early, and the company itself…
AtaiBeckley just had a breakout moment, with its share price soaring on news that Eli Lilly is in talks to buy the psychedelic drug developer….
AlphaTON Capital Corp. (NASDAQ: ATON) is moving higher today, with the stock up about 23% to 0.2926 from a prior close of 0.2385. Shares have…
The Advanced Research Projects Agency for Health (ARPA-H) is committing up to $160 million to scientists building platforms for highly personalized genetic treatments, with a…
July 09, 2026
First-Ever Clinical Program in Peeling Skin Syndrome Advances as FDA Clears Quoin’s QRX003
A rare disease with no approved treatments and no prior formal clinical development now has its first company-sponsored clinical program. Quoin Pharmaceuticals (NASDAQ: QNRX) announced…